A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Latest Information Update: 30 Jun 2025
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IZALCO
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
Most Recent Events
- 24 Jun 2025 The protocol has been amended to addition in treatment arm and size and addition in pharmacokinetic primary endpoints
- 24 Jun 2025 Planned number of patients changed from 71 to 118.
- 24 Jun 2025 Planned End Date changed from 1 Mar 2027 to 12 May 2028.